OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-20.98%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$322M
AUM Growth
-$149M
(-32%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-8.31%
Top 10 Holdings %
Top 10 Hldgs %
58.84%
Holding
48
New
9
Increased
13
Reduced
15
Closed
3
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.68M |
| 2 |
Fulcrum Therapeutics
FULC
|
$3.22M |
| 3 |
908 Devices
MASS
|
$3.16M |
| 4 |
Edgewise Therapeutics
EWTX
|
$2.94M |
| 5 |
Mersana Therapeutics
MRSN
|
$2.83M |
Top Sells
| 1 |
Celldex Therapeutics
CLDX
|
$22.1M |
| 2 |
Cytokinetics
CYTK
|
$6.39M |
| 3 |
BridgeBio Pharma
BBIO
|
$5.47M |
| 4 |
Semler Scientific
SMLR
|
$5.05M |
| 5 |
Sutro Biopharma
STRO
|
$4.85M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
MacroGenics
MGNX
$121M
| $3.32M | 1.03% |
376,400
-85,600
| -19% | -$754K |
|
27
Verastem
VSTM
$585M
| $3.28M | 1.02% |
193,750
| – | – |
|
|
28
Fulcrum Therapeutics
FULC
$353M
| $3.22M | 1% |
+136,000
| New | +$3.22M |
|
|
29
908 Devices
MASS
$214M
| $3.16M | 0.98% |
+166,406
| New | +$3.16M |
|
|
30
Edgewise Therapeutics
EWTX
$1.54B
| $2.94M | 0.91% |
+303,000
| New | +$2.94M |
|
|
31
Mersana Therapeutics
MRSN
$34.8M
| $2.83M | 0.88% |
+28,400
| New | +$2.83M |
|
32
Hyperfine
HYPR
$88M
| $2.7M | 0.84% |
763,075
| – | – |
|
33
Synlogic
SYBX
$17.4M
| $2.36M | 0.73% |
65,613
+8,946
| +16% | +$322K |
|
34
ProQR Therapeutics
PRQR
$256M
| $2.2M | 0.68% |
2,425,000
+989,490
| +69% | +$896K |
|
35
Neurogene
NGNE
$284M
| $1.49M | 0.46% |
39,500
-12,865
| -25% | -$484K |
|
|
AVEO
36
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $1.34M | 0.42% |
240,000
-23,400
| -9% | -$131K |
|
|
LENZ
37
LENZ Therapeutics
LENZ
$1.12B
| $1.3M | 0.4% |
+36,500
| New | +$1.3M |
|
38
Liquidia Corp
LQDA
$2.52B
| $1.28M | 0.4% |
178,800
+162,000
| +964% | +$1.16M |
|
39
Modular Medical
MODD
$39.7M
| $1.17M | 0.36% |
+266,100
| New | +$1.17M |
|
40
Avalo Therapeutics
AVTX
$139M
| $1.05M | 0.33% |
505
-2
| -0.4% | -$4.17K |
|
|
NCNA
41
NuCana
NCNA
$5.8M
| $878K | 0.27% |
176
-62
| -26% | -$309K |
|
42
Repare Therapeutics
RPTX
$73.9M
| $793K | 0.25% |
+55,678
| New | +$793K |
|
|
43
Sutro Biopharma
STRO
$85.6M
| $740K | 0.23% |
89,980
-590,020
| -87% | -$4.85M |
|
44
Journey Medical
DERM
$187M
| $324K | 0.1% |
+67,000
| New | +$324K |
|
|
BLRX
45
BioLineRX
BLRX
$15.5M
| $29K | 0.01% |
417
| – | – |
|
|
46
BridgeBio Pharma
BBIO
$9.91B
| – | – |
-328,100
| Closed | -$5.47M |
|
47
MEI Pharma
MEIP
$149M
| – | – |
-65,750
| Closed | -$3.51M |
|
|
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-165,778
| Closed | -$3.6M |
|